You are here

Bioiberica will be exhibiting at CPhI Russia 2017, stand 231 from the 28th to the 30th March

27 Mar 2017
  • Bioiberica’s Human Health and Heparin Business Units will participate at the CPhl Russia fair, one of the most important events for the pharmaceutical sector 
  • The Russian pharmaceutical market is positioned at the forefront of pharmaerging markets


The third edition of the CPhI Russia tradeshow, held in Moscow from the 28th to the 30th March, will bring together world leading firms specializing in the manufacture and distribution of active ingredients and finished pharmaceutical products. This year, Bioiberica’s Human Health and Heparin Business Units will present their Pharmaceutical Active Principles (chondroitin sulfate, glucosamine, hyaluronic acid, and heparin) and branded ingredients (Mobilee, b-2Cool, Tendofit and Acti-Joint). 

The CPhl Russia fair is a unique opportunity to establish strategic contacts with the leading pharmaceutical firms in Russia. The Russian pharma market is positioned at the forefront of pharmerging markets and is projected to reach a value of US $31.2 billion by 2019.

The Russian Government's ambitious Pharma 2020 plan, introduced in 2009, includes funding of nearly US$5 billion with the aim of dramatically increasing domestic pharmaceutical manufacturing and R&D capabilities.

Related News

19 Apr 2022

This endorses the company's commitment and responsibility to strengthen and consolidate its ethical corporate governance based on the strictest legal and regulatory standards.

11 Apr 2022

Since Bioiberica was first established, our mission has been to improve the health of people, animals and plants worldwide. Our purpose – to take care of life sustainably through science – is driven by the desire to build a better future.